Creating Possible with CAR T During COVID-19

During the pandemic, global travel restrictions disrupted movement across the world. Senior Manager, Supply Chain and Logistics, Pieter van Hengel, discusses how Kite was able to find innovative solutions to ensure patients continued to receive CAR T-cell therapy, despite logistical hurdles faced during COVID-19.
Note: The video depicts a period during COVID-19 before Kite’s Amsterdam facility was approved, allowing for end-to-end manufacturing in Europe. For patients in the U.S. receiving Kite’s CAR T-cell therapies, the manufacturing process occurs entirely within the U.S.
For more information about CAR T-cell therapy, visit:
Website: www.kitepharma...
Twitter: / kitepharma
Facebook: / kiteagileadcompany
LinkedIn: / kite-pharma-inc-